I wanted to share a deep dive I put together analyzing the current status of Hikma v. Amarin at the Supreme Court level and the likelihood of the Solicitor General supporting certiorari. It walks through the legal pathway, strategic implications, and potential impact on Amarin's value and positioning, especially in light of recent retail and legal community engagement (e.g., north40000's filings and Hazel-Atlas references). It analyzed all available legal documents I uploaded in the past year leading up to where we currently sit with the SG.
📄 Memo Title: SCOTUS Analysis of Hikma v. Amarin and SG Certiorari Outlook
Would love to hear the board's take, especially on how you all view the SG’s potential stance, the fraud angle that’s been raised, and what it could mean for AMRN's leverage in 2025.
Note: Please disregard the memo letterhead at the top. It was unintentionally formatted as a formal internal memorandum addressed to Amarin Pharma. The content that follows is an independent legal analysis prepared for discussion and strategic insight, not an internal company document.
If you guys like the format, I have many others prepared on various Amarin topics that you might find interesting or informative. Happy to share weekly.
Market Data 
Markets 
